Across TCGA pan-cancer cohorts, OR2C3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR2C3 data layer compared with 17 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher OR2C3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2C3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
KICH, PRAD, and ESCA are the cancer types where OR2C3 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.